Integrative Training in Oncogenic Signaling
致癌信号综合培训
基本信息
- 批准号:9312769
- 负责人:
- 金额:$ 31.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-07-08 至 2021-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
PROJECT SUMMARY/ABSTRACT
This proposal seeks National Cancer Institute (NCI) support for an exciting new Integrative Training in
Oncogenic Signaling (ITOS) Program that has been developed by a select group of cancer scientists affiliated
with the Hollings Cancer Center (HCC) at the Medical University of South Carolina (MUSC). The ITOS
Program takes place in this active and growing medical center environment with state-of-the-art facilities, a
vibrant NCI-designated cancer center, and an active Office of Postdoctoral Affairs. Led by a Program Director
with an exceptionally strong cancer research background and leadership experience, the ITOS Program will
select and support the placement of trainees in experienced, well-funded, productive laboratories led by the
Program Faculty who reside in an interactive, multi-departmental research environment with extensive
resources. Each trainee will have a primary mentor and one or two secondary mentors with complementary
expertise to ensure distinct and valuable perspectives that will enhance the overall cancer-related research
training experience. The objectives of this training program are to provide proactive mentoring and oversight
and research training in cutting-edge methodology; to develop useful academic and essential career
development skills; to foster collaborative, interdisciplinary interactions with faculty and other trainees; and to
provide exposure to current cancer research discoveries and how these are being translated into novel
approaches to prevention, diagnosis, and treatment of cancer.
Slated to train five postdoctoral trainees each year for five years, this robust training opportunity has seven
programmatic components essential in obtaining the aforementioned objectives. These include the following
components: 1) 33 Program Faculty who share common interests in cancer research and will provide the
essential mentoring for trainees; 2) one to two year experiences in Program Faculty laboratories found within
the vibrant HCC research environment; 3) an ITOS Program Research Club providing an engaging community
forum for the trainees and Program Faculty to discuss work in progress as well as the latest discoveries in
cancer science; 4) shared research resource workshops and tailored training with experts in cutting-edge
biotechnologies; 5) interdisciplinary engagement with trainees in HCC-sponsored thematic research retreats,
symposia, work in progress meetings, and seminars; 6) career development workshops and courses that will
equip trainees for independent success; and 7) opportunities to network nationally at a minimum of two
professional conferences each year. In summary, the ITOS Program will offer distinct experiences and
opportunities only afforded to the selected ITOS Fellows, and the program, led by an outstanding cadre of
Program Faculty, is anticipated to be highly attractive to emerging junior investigators locally and nationally.
项目概要/摘要
该提案寻求美国国家癌症研究所 (NCI) 支持一项令人兴奋的新综合培训
致癌信号 (ITOS) 程序由一组选定的附属癌症科学家开发
与南卡罗来纳医科大学 (MUSC) 的霍林斯癌症中心 (HCC) 合作。信息技术操作系统
项目在这个活跃且不断发展的医疗中心环境中进行,拥有最先进的设施、
充满活力的 NCI 指定癌症中心,以及活跃的博士后事务办公室。由项目总监领导
凭借极其强大的癌症研究背景和领导经验,ITOS 计划将
选择并支持将学员安置在由以下机构领导的经验丰富、资金充足、富有成效的实验室
项目教师居住在一个互动的、多部门的研究环境中,拥有广泛的研究成果
资源。每个学员将有一名主要导师和一到两名辅助导师
专业知识,以确保独特和有价值的观点,从而增强整体癌症相关研究
培训经验。该培训计划的目标是提供主动指导和监督
以及尖端方法的研究培训;发展有用的学术和重要的职业
发展技能;促进与教师和其他学员的协作、跨学科互动;并到
提供当前癌症研究发现以及如何将这些发现转化为新发现
预防、诊断和治疗癌症的方法。
这个强大的培训机会预计在五年内每年培训五名博士后学员,其中七名
实现上述目标所必需的计划组成部分。这些包括以下内容
组成部分: 1) 33 名项目教师,他们在癌症研究方面有着共同的兴趣,并将提供
对受训者的重要指导; 2)在项目学院实验室中拥有一到两年的经验
充满活力的 HCC 研究环境; 3) ITOS 项目研究俱乐部提供了一个有吸引力的社区
学员和项目教师讨论正在进行的工作以及最新发现的论坛
癌症科学; 4)与前沿专家共享研究资源研讨会和定制培训
生物技术; 5) 在 HCC 赞助的主题研究静修中与学员进行跨学科接触,
专题讨论会、进展中会议和研讨会; 6) 职业发展研讨会和课程
帮助学员取得独立成功; 7) 至少有两次在全国建立人际网络的机会
每年召开专业会议。总之,ITOS 计划将提供独特的体验和
机会只提供给选定的 ITOS 研究员,该计划由杰出的骨干领导
预计该项目对当地和全国的新兴初级研究人员具有高度吸引力。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Philip H Howe其他文献
Philip H Howe的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Philip H Howe', 18)}}的其他基金
TGFbeta-regulated epithelial-mesenchymal transition (EMT)
TGFβ调节的上皮间质转化(EMT)
- 批准号:
10548115 - 财政年份:2011
- 资助金额:
$ 31.8万 - 项目类别:
TGFbeta-regulated epithelial-mesenchymal transition (EMT)
TGFβ调节的上皮间质转化(EMT)
- 批准号:
10292840 - 财政年份:2011
- 资助金额:
$ 31.8万 - 项目类别:
相似国自然基金
硫化氢抑制采后枸杞乙烯生物合成及其信号转导的机理研究
- 批准号:32360612
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
TRIM21-Hippo-Yap信号转导新机制在结肠癌转移中的作用及其靶向干预研究
- 批准号:82373142
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
荔枝生理落果信号转导与功能基因调控机理
- 批准号:32330092
- 批准年份:2023
- 资助金额:220 万元
- 项目类别:重点项目
基于“丛枝菌根真菌-激素信号转导-转录因子-L/ODC基因”调控路径解析苦参生物碱生物合成的调控机制
- 批准号:82304678
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
GH/GHR信号转导在肝脏胆汁酸代谢调控中的作用及机制研究
- 批准号:32300991
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Understand Non-canonical RAS Signaling in Clonal Hematopoietic Disorders
了解克隆性造血疾病中的非典型 RAS 信号转导
- 批准号:
10571352 - 财政年份:2023
- 资助金额:
$ 31.8万 - 项目类别:
The context-dependent role of Caveolin-1 as a driver of cellular adaptation in Ewing Sarcoma
Caveolin-1 作为尤文肉瘤细胞适应驱动因素的背景依赖性作用
- 批准号:
10662162 - 财政年份:2023
- 资助金额:
$ 31.8万 - 项目类别:
Structure and Function of the SHOC2 Holophosphatase Complex in RAS-driven Cancer
SHOC2 全磷酸酶复合物在 RAS 驱动的癌症中的结构和功能
- 批准号:
10662750 - 财政年份:2023
- 资助金额:
$ 31.8万 - 项目类别:
Characterizing and Targeting ERBB2 Mutations in Invasive Lobular Carcinoma
侵袭性小叶癌中 ERBB2 突变的特征和靶向
- 批准号:
10749213 - 财政年份:2023
- 资助金额:
$ 31.8万 - 项目类别:
Dissecting the tumor cell-immune TME axis to identify therapeutically actionable vulnerabilities that potentiate immunotherapy in GBM
剖析肿瘤细胞免疫 TME 轴,以确定可增强 GBM 免疫治疗的治疗上可操作的漏洞
- 批准号:
10743534 - 财政年份:2023
- 资助金额:
$ 31.8万 - 项目类别: